Adverse Events After 177Lu-PSMA-617 as Determined by Blood Tests (n = 121) or Physician Reports (n = 145)
| Organ system | Category | Evaluated for N | All grades | Grade 3–4 |
| Blood and lymphatic disorders | Leukopenia | 121 | 48 (40%) | 4 (3%) |
| Anemia | 145 | 50 (34%) | 15 (10%) | |
| Thrombocytopenia | 121 | 38 (31%) | 5 (4%) | |
| Gastrointestinal disorders | AST elevation | 121 | 27 (19%) | 0 (0%) |
| ALT elevation | 121 | 11 (8%) | 0 (0%) | |
| Xerostomia | 145 | 11 (8%) | 0 (0%) | |
| Nausea | 145 | 9 (6%) | 0 (0%) | |
| Dysgeusia | 145 | 6 (4%) | 0 (0%) | |
| Ascites | 145 | 2 (1%) | 0 (0%) | |
| Biliary obstruction | 145 | 0 (0%) | 1 (1%) | |
| General disorders | Fatigue | 145 | 19 (13%) | 1 (1%) |
| Pain | 145 | 5 (3%) | 0 (0%) | |
| Ileus | 145 | 1 (1%) | 0 (0%) | |
| Urinary disorders | Renal failure | 121 | 14 (12%) | 0 (0%) |
| Urinary tract infection | 145 | 1 (1%) | 0 (0%) | |
| Cardiovascular disorders | Edema | 145 | 2 (1%) | 0 (0%) |
| Lung embolism | 145 | 0 (0%) | 3 (2%) | |
| Respiratory, thoracic, and mediastinal disorders | Pleural effusion | 145 | 1 (1%) | 0 (0%) |
| Dyspnea | 145 | 1 (1%) | 0 (0%) | |
| Neurologic disorders | Vertigo | 145 | 1 (1%) | 0 (0%) |
| Stroke | 145 | 0 (0%) | 2 (1%) | |
| Musculoskeletal disorders | Bone facture | 145 | 0 (0%) | 3 (2%) |
AST = aspartate aminotransferase; ALT = alanine aminotransferase.